Rachel Houten

University of Liverpool — United Kingdom

Health Professions · Health Sciences

12h-index638citations75works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Geriatric Care and Nursing Homes(8), Musculoskeletal pain and rehabilitation(6), Health Systems, Economic Evaluations, Quality of Life(6), Pain Management and Treatment(6), Healthcare cost, quality, practices(5)

Publications74 total

Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis
PharmacoEconomics - Open·2024· 5 citedOpen Access
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
Health Technology Assessment·2024· 1 citedOpen Access
In Reply: Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results from a Randomized Controlled Trial
Neurosurgery·2024· 1 citedOpen Access
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023Open Access
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023· 9 citedOpen Access
EE561 An Examination of Healthcare Provider Costs Associated with Paper-Based Consent
Value in Health·2023Open Access
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 1 citedOpen Access
Informed consent failures: National Health Service Resolution data
British journal of surgery·2023· 5 citedOpen Access
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 2 citedOpen Access
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
Health Technology Assessment·2023· 6 citedOpen Access
Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled Trial
Neurosurgery·2022· 26 citedOpen Access
Screening trials of spinal cord stimulation for neuropathic pain in England—A budget impact analysis
Frontiers in Pain Research·2022· 12 citedOpen Access
Spinal Cord Stimulation for Neuropathic Pain in England From 2010 to 2020: A Hospital Episode Statistics Analysis
Neuromodulation Technology at the Neural Interface·2022· 7 citedOpen Access
Table of Contents
Neuromodulation Technology at the Neural Interface·2021Open Access
To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients’ View From the TRIAL-STIM Randomized Controlled Trial
Neuromodulation Technology at the Neural Interface·2020· 33 citedOpen Access
A systematic review of health state utility values for thyroid cancer
Quality of Life Research·2020· 28 citedOpen Access
Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? A randomised controlled trial
Pain·2020· 87 citedOpen Access
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 6 citedOpen Access
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 3 citedOpen Access
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Health Technology Assessment·2020· 38 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Alan Haycox(26), Sarah Richards(24), Maureen Gambles(21), Sheila Harper(21), Terri O’Brien(21), Kate Nolan(21), John Ellershaw(21), Angela Boland(14), Elizabeth Perkins(12), Rui Duarte(10), Sophie Beale(10), Nigel Fleeman(9), Marty Chaplin(8), Y Dündar(8), Sarah J Nevitt(8), James Mahon(7), Sam Eldabe(6), Morag Brookes(6), Jenny Earle(6), Jill A. Bell(6)